Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For 2 years after the ARYC dilution the stock traded at 0.0001
ARYC is up over 10,000% in the same time while AVDX is down the same amount.
Just like ARYC, the parent of AVDX, which diluted from 50M to 1.055B three years ago years ago.
The apple doesn't fall far from the tree.
me too, thanks for the warning
wow I didn't think it would be that bad- terrible dilution...
Did you see the 13g here! Holy cow.....they diluted this junk more than I expected. 1.4 billion added to the OS!!! Glad you pulled your bid?
As of last May:
Total of 1,439,428,082 shares of Common Stock outstanding
Dilution dilution dilution.
Sad and depressing
Buyer Beware: AVDX heavy dilution occurring. This company has diluted the hell out of its stock in the past 2 years going from 36 million outstanding shares to 1.46 Billion shares as of May 2018. This is why share price has declined from.80+ per share, down to .0001/share.
One other thing a reverse split may not be necessary for AVDX!!
Apparently financing is readily available.
Some heavyweights are now involved in bringing the technology to market!
Hold on!!
My sources tell me big things are happening behind the scenes at AVDX!!
It’s down 97% today. LOL
IMO this stock is going to uplift soon. People should be buying it hand over fist.
Yes I remember how it killed ARYC going from 0.10 to 0.0001 when they diluted the heck out of the stock going from 50 Million O/S to 1Billion shares
Thanks, bud, I did cancel, I can find a better place for $50. Also, appreciate the other two posts on dilution(not from sales)
And I have nothing against the company itself, but dilution kills any stock. I see several over here making positive comments about AVDX but reality is that share price will continue to decline. In all probability, don’t be surprised to see share price drop well into the triple digits.
AVDX went from 30 million shares outstanding in 2015 to 336 million last year. We have no idea what they are at now. Ovadx needs funding and it’s not coming from sales, that’s for sure.
Save your money. This company is diluting the hell out of itself to survive
jhols, do you think we have a repeat of that happening here, at least somewhere in the .000's? Also, my bid for $ 50K at .001 is not showing anywhere, what gives?
Gotcha, I hit big with Aryc when it was .0004
@.0001, that would have cost you $5,000, and might have been worth it some day, LOL. I used to buy 10's of millions of .0001's, but they ended up worthless, imagine that. Actually that's not entirely true, I did recover my costs on a few stocks.
My 50,000,000 didn’t get filled
jhols, I got a bid in for 5000 @.001, let's see what'll happen. Only $50, hope it goes through. I just do that so I can watch it on my account page.
Because it’s junk
jhols, I got your PM but I don't have PM to answer.
Only 295 shares traded today, so I don't think that the 0.0001 is a good representation. But I have no idea where this company is heading, whether they can resolve their issues with the SEC>
AVDX just crashed to .0001 , I’m buying ! Anybody want to tell me why not at that price?
You're welcome, and best of luck!!
Thank you I appreciate the feed back
AVDX was available to trade yesterday on Oct. 3rd. If there is insignificant shareholder interest in buying due to imminent registration revocation by the SEC Admin Law Judge the stock would have no volume.
Question ? Will this trade again . Thanks
What do you guys think this will fall to when trading resumes?
AVDX SEC Suspension for severely delinquent Financials/Filings:
https://www.sec.gov/litigation/suspensions/2018/34-84189.pdf
Order:
https://www.sec.gov/litigation/admin/2018/34-84188.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2018/34-84188.pdf
OvaDx used to be their premier product. Now it's not even mentioned in the Avant Diagnostics website. Since the merger with Theranostics, Theralink is their premier product.
Avant tried (unsuccessfully) for years to get funding to get OvaDx FDA approved. There are rumors that Arrayit Corp. (ARYC) which developed the test may be getting the rights to OvaDx back. Time will tell. But Arrayit does have a test submitted to the FDA for approval and met with the FDA on July 2. Arrayit hasn't said which test, but we are hoping is OvaDx.
Expecting FDA approval very nice
The Company’s premier product is OvaDx®, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company believes this test will be approved by the U.S. Food and Drug Administration (“FDA”) as the first pre-symptomatic screening test for ovarian cancer in the United States,
Well I was thinking of jumping in here along with my aryc. Not so sure now what’s happening here with the games being played. R/s and all. Not share holder friendly.
Sorry it’s difficult to understand what you are talking about. Can you please explain yourself?
I JUST SOLD MY FINAL aon 1708 SHARES AT $0.0552/SHARE ON AN OPEN ORDER TO SELL THEM AT $0.031. NOW THAT JUST MAY BE THE MOST AMAZING THING I HAVE EVER SEEN A MARKET MAKER DO. I LOST CASH ON THIS DOG. NOT THE FIRST BUT THAT'S SO ODD IT MAY NOT BE DEAD YET? HARD TO BELIEVE. WORTH WATCHING AFTER ALL. MAJOR POSITION LIQUIDATED LAST MONTH AT MY PRICE BUT A PARTIAL SELL OF COURSE. FORGOT THE AON SPECIFICITY...AM I MISSING SOMETHING ON THIS PUMP AND DUMP?
40.0552/SHARE ON AN OPEN ORDER TO SEL AT $0.031/SHARE.
You been say this for years
Maybe ARYC took it back in which case it is a positive, because AVDX was unable to do anything with it.
Live and learn.
OvaDx is not even mentioned anymore in the new revised Avant website.
What did they do with the OvaDx IP?
https://www.avantdiagnostics.com/about
https://www.avantdiagnostics.com/product-pipeline
Avant Diagnostics to Present at LD Micro
PR Newswire
WASHINGTON, June 1, 2018
WASHINGTON, June 1, 2018 /PRNewswire/ -- Avant Diagnostics, Inc. (OTC:AVDX) (the "Company," or AVDX), a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology, today announced that its new President & CEO, Mick Ruxin, M.D., will be presenting a corporate overview at the 8th Annual LD Micro Invitational on June 5th, 2018 at 2:00pm PT. Management will be available to meet with interested parties for one-on-one meetings throughout the event.
Presentation Details
Event: 8th Annual LD Micro Invitation
Date: Tuesday, June 5, 2018
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
Location: Luxe Sunset Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049
Website: https://www.ldmicro.com/events
About Avant Diagnostics, Inc.
Avant Diagnostics, Inc. (Avant) is a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology. Avant provides personalized medicine data through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Theralink®, was developed to empower community physicians and clinical trial investigators with actionable information to make time sensitive treatment decisions for their patients. Theralink® was designed to inform physicians which treatments are likely to be effective for their patients at any given moment in time, and also identify which treatments are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.
Avant Diagnostics' Pharma Services Business will help drug companies accelerate their drug discovery programs and facilitate development of companion diagnostics. Avant's data generating technologies will also:
Stratify subjects entering clinical trials (reduces trial costs with smaller cohorts)
Monitor on and off target drug effects (regulatory filings)
Quantify phosphoproteome to identify activation of resistance or compensatory pathways post-treatment
Evaluate potential proteomic markers for combination therapies
Repurpose existing therapies for new indications (off-patent drugs and market expansion)
For further information please visit www.Avantdiagnostics.com.
Who are these guys that have been appointed?
Are they the one’s providing the financing in return for the A shares, that will give them control of AVDX?
Nothing is clear as usual.
What a disaster.
Live and learn!
Wow a lot of debt and shares creation for a small company with not much to show for it. Something doesn't smell right.
Avant Diagnostics Restructures, Issues Private Placement
May 30, 2018 | staff reporter
NEW YORK (GenomeWeb) – Avant Diagnostics said today that it has entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
Avant designated and sold through the agreement 650,000 shares of Series A preferred stock, which will control a majority of the voting power of the company. Avant now plans a reverse stock split of its common stock, which will create 15 million shares of common stock outstanding. All outstanding shares of the series A preferred stock are to be converted into shares of common stock.
As part of the closing, Jeffrey Busch was named chairman of Avant's board of directors, John Brugmann was appointed to the board, and Mick Ruxin was made a board member and named president and CEO of Avant.
Additionally, certain company debtholders exchanged $1,824,856 owed for 516,155 shares of the series A preferred stock, roughly 26 million shares of series B preferred stock, and new notes for a principal amount of $265,091. Each share of series B preferred stock will be converted to 10 shares of the company's common stock. Some debtholders also waived their future rights to and security interests in Avant's assets.
Avant's lead product is its Theralink phosphoproteomics assay for assessing the activity of cancer signaling pathways and guiding therapy. It acquired the assay when it acquired Theranostics Health in 2016.
Now that the Amarantus tests like LymPro were taken back by Amarantus, Avant consists mostly of Theralink now, the product that came from the Theranostics company during the triple merger. And Ovadx the original Avant product is a footnote. Theranostics had some revenue. We don't know anymore because they have not filed financials for a while.
I don't know why the last CEO quit, but IMO I suspect he did not like the financial games being played on the company by other players like Amarantus CEO who was a director and other directors/basketball players. As a result serious dilution of the stock took place. Maybe the new CEO will clean up the slate, but who knows.
https://www.avantdiagnostics.com/product-pipeline
https://www.genomeweb.com/molecular-diagnostics/avant-completes-acquisitions-amarantus-theranostics-health#.Ww318EgvzIU
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1189
|
Created
|
04/15/15
|
Type
|
Free
|
Moderators |
March 7,2016
Avant Diagnostics (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), today announced that the companies have jointly entered into a letter of intent for Avant to acquire Theranostics Health Incorporated ("THI"), adding key CLIA laboratory and intellectual property capabilities to Avant and Amarantus' previously announced diagnostics merger. Theranostics currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue.
Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.
OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.
As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market.
Investment Highlights
OvaDx®
The market's first large panel biomarker screening test for ovarian cancer
OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.
Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1® and transvaginal ultrasound.
Clinicians will appreciate the following features of this product:
Ovarian Cancer
The Dire Need for Early Detection of the "Silent Killer"
Ovarian cancer is the 11th most common cancer among women and the fifth-leading cause of cancer-related death among women. According to the Centers for Disease Control, Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but accounts for only about 3% of all cancers in women. When ovarian cancer is found in its early stages, treatment is most effective.
Often called "the silent killer," however, ovarian cancer is rarely caught early. Many times there are no symptoms until the disease has progressed to advanced stages. About 20% of ovarian cancers are found at an early, localized stage, and 94% of those patients live longer than five years after diagnosis, according to the American Cancer Society.
While regular women's health exams, knowledge of symptoms and risks, and screenings can be important ways to detect ovarian cancer, there is much research being done to develop new tests to accurately diagnose the disease at an early stage.
Management
Avant Diagnostics' progression toward FDA approval and commercialization of OvaDx® is spearheaded by a management team with a rich history of experience in executive leadership, accounting, corporate sales, marketing and financing for numerous industries.
Gregg Linn | President/CEO
Gregg Linn joined Avant Diagnostics as president and CEO in February December 2015. Prior to these roles, Linn served as the company's COO and CFO since December 2012. Since 2008, Linn served as the president and managing member of Issuers Capital Advisors, LLC, and since 2001 served as CEO and managing member of Red Rock Advisors, LLC. Both firms specialize in providing strategic financial and business development advisory services to public and non-public companies, with emphasis on capital formation, mergers and acquisition and management of the public side of small cap publicly traded companies. From 2004 to 2007, he was COO and CFO of Vital Living, Inc., a Phoenix, Arizona-based publicly traded nutritional supplements company. Prior to 2004, Linn served as CFO of several other public and privately held companies, senior financial management positions at Fortune 500 companies, as well as worked as a senior analyst at Shearson Lehman. Linn received an undergraduate degree in accounting and business from Michigan State University in 1984 and a Master Degree in Business Administration, summa cum laude, from Pace University-NYC in 1992. Linn is a certified public accountant.
Joseph Roth
Joseph Roth has spent more than three decades as a corporate sales, marketing and management executive with Fortune 50 companies as well as entrepreneur opportunities. For the past five years he has been self employed as a consultant to small and medium sized companies and C-level executives. From 2008-2010, he was COO of ShopBox, LLC, a business process outsourcing company specialized in the execution of web-based kiosk marketing strategies. He was responsible for securing partnership deals with NASCAR, NFL, NHL and NBA leagues, teams and franchises. From 2003 to 2008, Roth was president of CMB Franchising, Inc., a licensed Area Developer of Extreme Pita Restaurants of Canada for Arizona and Nevada. During this time he oversaw the construction, development and operations of 10 stores generating a 25% increase over the second highest volume franchise in the U.S. From 1996-2003, Roth was managing partner of Cypress Staffing Services, LLC, a company he founded in 1999 that provides private duty home care throughout Central Arizona. Cypress grew from scratch to become the largest company in Arizona within its industry category in less than four years.
Randall Letcavage
Randall Letcavage brings in excess of 25 years of business experience specializing in the financial markets, investment banking and business consulting. Currently, Letcavage is chairman, CEO, and president of Premier Holding Corp., which is publicly traded on the OTCQB exchange. For the past 20 years Letcavage has been an investment banker widely recognized for numerous achievements as well as his role of founder, officer and director of the iCapital Group, which includes iCapital Finance Inc, iCapital Advisory LLC and iCap Development LLC (A National "CDE" Community Development Entity – Certified by the U.S. Treasury Department). Letcavage has advised numerous clients on various transactions and financings in a wide range of industries, including technology, healthcare, financial services, entertainment, energy and green initiatives.
Avant Diagnostics, Inc | QualityStocks Investor Relations |
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Daily Chart
Weekly Chart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |